Johnson & Johnson's Icotrokinra Outperforms Deucravacitinib in Phase 3 Psoriasis Trials with Superior Skin Clearance and Favorable Safety Profile

Gelonghui September 17 | Johnson & Johnson reported that the experimental oral psoriasis drug icotrokinra demonstrated superior skin clearance compared to Bristol-Myers Squibb's deucravacitinib in two Phase III clinical trials, while maintaining an adverse event rate similar to that of the placebo.